Anatomical pathology

UK's First Rollout of AI-based Cancer Detection for NHS Patients as Pathology Provider LDPath Teams Up with Ibex Medical Analytics

Retrieved on: 
Tuesday, June 30, 2020

In recent years, a global increase in cancer cases has coincided with a decline in the number of pathologists around the world.

Key Points: 
  • In recent years, a global increase in cancer cases has coincided with a decline in the number of pathologists around the world.
  • Limited availability of pathologists requires couriers to transport glass slides containing tissue samples between different locations to access expert opinions.
  • LDPath pathologists will be alerted in the event of significant discrepancy between their diagnosis and the algorithm's findings (e.g.
  • "We are proud to be the first UK pathology provider to integrate AI into the digital pathology workflow by partnering with Ibex to improve cancer diagnosis," said Sanj Lallie, Director of Operations at LDPath.

The Lymphoma Research Foundation Hosts Inaugural Swirl: America, An At Home Tasting Virtual Fundraiser

Retrieved on: 
Monday, June 29, 2020

NEW YORK, June 29, 2020 /PRNewswire-PRWeb/ --The Lymphoma Research Foundation (LRF ) the nation's largest nonprofit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma community held its annual wine tasting event online on Thursday, June 25.

Key Points: 
  • NEW YORK, June 29, 2020 /PRNewswire-PRWeb/ --The Lymphoma Research Foundation (LRF ) the nation's largest nonprofit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma community held its annual wine tasting event online on Thursday, June 25.
  • Swirl: America, An At Home Tasting Event raised more than $20,000 to help fund research to fight lymphoma and is now available on-demand nationwide.
  • Lisa, who is passionate about helping to stop lymphoma and has family members affected by the disease, is in her inaugural year as an LRF spokesperson.
  • The Lymphoma Research Foundation (LRF) is the nation's largest non-profit organization devoted to funding innovative research and serving the lymphoma community through a comprehensive series of education programs, outreach initiatives and patient services.

Swedish Healthcare Region to Realize Integrated Diagnostics - Expands IT Solution From Sectra With Digital Pathology

Retrieved on: 
Monday, June 29, 2020

The healthcare region already uses Sectra's software for handling medical images, which will now be expanded to also include digital pathology as it digitizes its pathology department.

Key Points: 
  • The healthcare region already uses Sectra's software for handling medical images, which will now be expanded to also include digital pathology as it digitizes its pathology department.
  • It is important that we can scale our solution at our own pace and Sectra's solution allows this.
  • The digital solution also provides pathologists with assistance at critical decision points, such as grading or performing more precise measurements.
  • Sectra's digital pathology solution will be integrated with Region Vstmanland's laboratory information system (LIS).

Swedish Healthcare Region to Realize Integrated Diagnostics - Expands IT Solution From Sectra With Digital Pathology

Retrieved on: 
Monday, June 29, 2020

The healthcare region already uses Sectra's software for handling medical images, which will now be expanded to also include digital pathology as it digitizes its pathology department.

Key Points: 
  • The healthcare region already uses Sectra's software for handling medical images, which will now be expanded to also include digital pathology as it digitizes its pathology department.
  • It is important that we can scale our solution at our own pace and Sectra's solution allows this.
  • The digital solution also provides pathologists with assistance at critical decision points, such as grading or performing more precise measurements.
  • Sectra's digital pathology solution will be integrated with Region Vstmanland's laboratory information system (LIS).

New Study Demonstrates the Ability of myPath® Melanoma to Accurately Classify Lesions Ruled Indeterminate by Standard Pathological Assessment

Retrieved on: 
Thursday, June 25, 2020

SALT LAKE CITY, June 25, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today that a new study published in Future Medicine demonstrates the ability of myPath Melanoma to accurately classify skin lesions ruled indeterminate by standard pathological review.

Key Points: 
  • SALT LAKE CITY, June 25, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, announced today that a new study published in Future Medicine demonstrates the ability of myPath Melanoma to accurately classify skin lesions ruled indeterminate by standard pathological review.
  • This validation study for myPath Melanoma demonstrates the ability of the test to accurately classify lesions which are ruled indeterminate by an expert dermatopathologist, said Nicole Lambert, president of Myriad International, Oncology and Womens Health.
  • The study evaluated 181 skin lesions of which 125 were ruled indeterminate by at least one of seven blinded dermatopathologists who reviewed the samples.
  • This data is consistent with multiple other clinical validation studies for myPath Melanoma which have demonstrated the ability of the test to delineate melanoma from benign skin lesions with high diagnostic accuracy.

NantHealth Announces Research Results that Advances Understanding of Tumor Treatment Resistance

Retrieved on: 
Thursday, June 25, 2020

Next-generation sequencing (NGS) of DNA has not revealed all the mechanisms underlying resistance to genomically matched drugs.

Key Points: 
  • Next-generation sequencing (NGS) of DNA has not revealed all the mechanisms underlying resistance to genomically matched drugs.
  • Researchers evaluated data from 1,417 tumors whole-exome tumor (somatic)/normal (germline) NGS and whole-transcriptome sequencing in order to examine transcriptomic silencing of putative driver alterations.
  • In this large-scale study, they also determined the frequency of tumor mutations being germline, rather than somatic, in these and an additional 462 tumors with tumor and normal exomes.
  • JCI Insight serves to fulfill the ASCIs objective to advance medical science through the publication of clinically relevant research reports.

2020 AACR | AnchorDx Unveiled A New Generation of Methylation Sequencing Technology, Aurora, towards the Development of A $100 Multi-Cancer Screening Test

Retrieved on: 
Thursday, June 25, 2020

This one-tube DNA methylation test provides a very practical and accessible solution for routine clinical applications.

Key Points: 
  • This one-tube DNA methylation test provides a very practical and accessible solution for routine clinical applications.
  • In addition, the test offers high sensitivity and specificity, short turn-around time and low cost.
  • A key advantage of the Aurora test comes from its novel and streamlined target enrichment and sequencing library preparation strategy, resulting in significantly increased sensitivity and specificity of detecting low-abundant ctDNA methylation signals.
  • This novel technology may lead to the development of a clinically feasible, $100 multi-cancer screening test in the near future.

Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Retrieved on: 
Monday, June 22, 2020

The clinical profile and tolerability of oral XPOVIO provides physicians and patients with a new treatment alternative to traditional intravenous chemotherapy regimens.

Key Points: 
  • The clinical profile and tolerability of oral XPOVIO provides physicians and patients with a new treatment alternative to traditional intravenous chemotherapy regimens.
  • Karyopharm will host a conference call today, Monday, June 22, 2020, at 12:30 p.m. Eastern Time, to discuss the FDAs approval of XPOVIO for the treatment of patients with relapsed or refractory DLBCL.
  • In June 2020, XPOVIO was approved by the FDA as a treatment for patients with relapsed or refractory diffuse large B-cell lymphoma.
  • Such forward-looking statements include those regarding Karyopharms beliefs regarding XPOVIOs ability to treat patients with relapsed or refractory diffuse large B-cell lymphoma and expectations related to other XPOVIO regulatory submissions.

Guardant Health Presents Data at AACR Virtual Annual Meeting II Showing Liquid Biopsy Highly Accurate in Detecting Early-Stage Colorectal Cancer

Retrieved on: 
Monday, June 22, 2020

REDWOOD CITY, Calif., June 22, 2020 (GLOBE NEWSWIRE) -- Guardant Health, Inc.(Nasdaq: GH), a leading precision oncology company, presents new data at the American Association for Cancer Research (AACR) Virtual Annual Meeting II demonstrating that its LUNAR-2 liquid biopsy is a highly sensitive test that can detect early-stage colorectal cancer (CRC).

Key Points: 
  • REDWOOD CITY, Calif., June 22, 2020 (GLOBE NEWSWIRE) -- Guardant Health, Inc.(Nasdaq: GH), a leading precision oncology company, presents new data at the American Association for Cancer Research (AACR) Virtual Annual Meeting II demonstrating that its LUNAR-2 liquid biopsy is a highly sensitive test that can detect early-stage colorectal cancer (CRC).
  • These results are consistent with previously reported data2 showing that the companys multi-modal, cancer-specific circulating tumor DNA (ctDNA) technology increases test sensitivity to deliver clinically meaningful results.
  • Our LUNAR-2 assay holds the promise to directly improve cancer screening rates by addressing patient non-compliance with a simple blood test.
  • This study confirms that our test can consistently detect early-stage colorectal cancer, said Dr. Kathryn Lang, Guardant Health Vice President of Outcomes and Evidence.

Inivata to Present Data at AACR Virtual Annual Meeting Highlighting Capabilities and Clinical Application of RaDaR™ Assay

Retrieved on: 
Monday, June 22, 2020

Research Triangle Park, NC, USA and Cambridge, UK, 22 June 2020 -- Inivata, a leader in liquid biopsy, will present data at the American Association for Cancer Research (AACR) Virtual Annual Meeting II in support of the capabilities and real-world application of the Companys newly launched RaDaR assay.

Key Points: 
  • Research Triangle Park, NC, USA and Cambridge, UK, 22 June 2020 -- Inivata, a leader in liquid biopsy, will present data at the American Association for Cancer Research (AACR) Virtual Annual Meeting II in support of the capabilities and real-world application of the Companys newly launched RaDaR assay.
  • The assay thereby offers promise for patients who are at higher risk of relapse who may benefit from adjuvant therapy.
  • Further data will be presented from a clinical setting, which demonstrates RaDaRs sensitive detection of ctDNA in early-stage non-small cell lung cancer (NSCLC).
  • Inivata has also launched the personalized RaDaR assay allowing the highly sensitive detection of residual disease and recurrence.